Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

키워드

참고문헌 (19)

1. Wong GLH, "How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?", J Hepatol, 76, pp.1249~1262 (2022)
2. Yip TCF, "HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues", J Hepatol, 70, pp.361~370 (2019)
3. Yip TC, "Hepatitis B surface antigen seroclearance in a cohort of 154, 740 patients with chronic hepatitis B : a 15-year follow-up study", Hepatol Int, 11(Suppl 1), pp.S75~ (2017)
4. Liang LY, "Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients", J Gastroenterol, 55, pp.899~908 (2020)
5. Sun Woong Kim, "Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus", Clinical and Molecular Hepatology, 28(1), pp.17~30 (2022), 대한간학회[DOI]
6. Chan HLY, "Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients", Antivir Ther, 16, pp.1249~1257 (2011)
7. Lung-Yi Mak, "Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B", Clinical and Molecular Hepatology, 29(1), pp.146~162 (2023), 대한간학회
8. Wang J, "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound", J Hepatol, 65, pp.700~710 (2016)
9. Takako Inoue, "Novel biomarkers for the management of chronic hepatitis B", Clinical and Molecular Hepatology, 26(3), pp.261~279 (2020), 대한간학회[DOI]
10. Liu Y, "Serum HBV RNA quantification : useful for monitoring natural history of chronic hepatitis B infection", BMC Gastroenterol, 19, pp.53~ (2019)
11. Cornberg M, "Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡", J Hepatol, 72, pp.539~557 (2020)
12. Jer-Wei Wu, "Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(4), pp.524~534 (2021), 대한간학회[DOI]
13. Carey I, "Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy", Hepatology, 72, pp.42~57 (2020)
14. Li J, "Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients", Chin Med J(Engl), 134, pp.1160~1167 (2021)
15. Sonneveld MJ, "Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels", J Hepatol, 76, pp.1042~1050 (2022)
16. Tada T, "HBcrAg predicts hepatocellular carcinoma development : an analysis using time-dependent receiver operating characteristics", J Hepatol, 65, pp.48~56 (2016)
17. Hosaka T, "Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues", Aliment Pharmacol Ther, 49, pp.457~471 (2019)
18. Tseng TC, "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load", Gastroenterology, 142, pp.1140~1149 (2012)
19. Yip TCF, "How do we determine whether a functional cure for HBV infection has been achieved?", Clin Gastroenterol Hepatol, 18, pp.548~550 (2020)

관련 논문AI추천